Double-edged sword role of miRNA-633 and miRNA-181 in human cancers
Pathology - Research and Practice · 2023
DOI: 10.1016/j.prp.2023.154701 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2023. Verfasst von Jitendra Gupta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Research, GLA University, Mathura 281406, U. P., India. Electronic address: jitendra.gupta@gla.ac.in. Hauptthemen laut MEDLINE: MicroRNAs, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 211 Literaturangaben. Gefördert von: Deanship of Scientific Research, King Khalid University.
Abstract (Originalsprache)
Understanding the function and mode of operation of microRNAs (miRNAs) in cancer is of growing interest. The short non-coding RNAs known as miRNAs, which target mRNA in multicellular organisms, are described as controlling essential cellular processes. The miR-181 family and miR-633 are well-known miRNAs that play a key role in the development and metastasis of tumor cells. They may facilitate either tumor-suppressive or oncogenic function in malignant cells, according to mounting evidence. Metastatic cells that are closely linked to cancer cell migration, invasion, and angiogenesis can be identified by abnormal levels of miR-181 and miR-633. Numerous studies have demonstrated their capacity to control drug resistance, cell growth, apoptosis, and the epithelial-mesenchymal transition (EMT) and metastasis process. Interestingly, the levels of miR-181 and miR-633 and their potential target genes in the basic cellular process can vary depending on the type of cancer cells and their gene expression profile. Such miRNAs' interactions with other non-coding RNAs such as long non-coding RNAs and circular RNAs can influence tumor behaviors. Herein, we concentrated on the multifaceted roles of miR-181 and miR-633 and potential targets in human tumorigenesis, ranging from cell growth and metastasis to drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Research, GLA University, Mathura 281406, U. P., India. Electronic address: jitendra.gupta@gla.ac.in.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
- Rawalpindi Medical University, Rawalpindi, Pakistan.
- Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Master's Programme Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Andrology Program, Faculty o…
- Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
- Department of Pharmaceutics and Pharmaceutical Technology, Taif University, Taif, Saudi Arabia.
Förderung
- Deanship of Scientific Research, King Khalid University
Zitieren
APA
Gupta, J., Suliman, M., Ali, R., Margiana, R., Hjazi, A., Alsaab, H. O., Qasim, M. T., Hussien, B. M., & Ahmed, M. (2023). Double-edged sword role of miRNA-633 and miRNA-181 in human cancers. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2023.154701
Vancouver
Gupta J, Suliman M, Ali R, Margiana R, Hjazi A, Alsaab HO, et al. Double-edged sword role of miRNA-633 and miRNA-181 in human cancers. Pathology - Research and Practice. 2023. doi:10.1016/j.prp.2023.154701
BibTeX
@article{Gupta2023,
author = {Gupta, Jitendra and Suliman, Muath and Ali, Rida and Margiana, Ria and Hjazi, Ahmed and Alsaab, Hashem O and Qasim, Maytham T and Hussien, Beneen M and Ahmed, Muhja},
title = {Double-edged sword role of miRNA-633 and miRNA-181 in human cancers},
journal = {Pathology - Research and Practice},
year = {2023},
doi = {10.1016/j.prp.2023.154701}
}
EUVIMED